United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News MaaT Pharma commences HERACLES Phase 2 trial for MaaT013 in battle against acute graft-versus-host disease MaaT Pharma, a French oncology company, has announced a significant milestone in its clinical research: the dosing of… bypharmanewsdailyOctober 13, 2018
